November 18, 2026

Grifols presents new AMBAR® data from a real-world observational study in patients with Alzheimer’s disease

  • New real-world evidence data from AMBAR® describe cognitive outcomes observed over 18 months in patients who underwent therapeutic plasma exchange (TPE) with albumin replacement in a real-world observational study
  • Across 1,201 sessions performed in 71 patients, outpatient TPE using peripheral venous access showed a favorable safety and tolerability profile
  • The results are being presented today at the 19th Clinical Trials on Alzheimer’s Disease Conference (CTAD) 2026 in Boston, U.S., and at the 78th Annual Meeting of the Spanish Society of Neurology (SEN) in Seville, Spain

 

Barcelona, Spain, November 18, 2026 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today presents new real-world evidence (RWE) data from the AMBAR® (Alzheimer Management by Albumin Replacement) program, contributing to the ongoing research evaluating the use of therapeutic plasma exchange (TPE) with albumin replacement in patients with mild cognitive impairment and mild to moderate Alzheimer’s disease.

The new data come from a real-world observational study conducted at Ace Alzheimer Center Barcelona that included 71 patients followed for 18 months. Patients received up to 21 TPE sessions with albumin replacement, performed on an outpatient basis and exclusively using peripheral venous access.

The cognitive outcomes suggest that the overall Mini-Mental State Examination (MMSE) score, one of the most widely used scales for assessing cognitive function, declined by 3.1 points over 18 months, equivalent to 2.5 points per year. This represents a lower rate of decline than the approximately 3.3 points per year reported in natural history studies of Alzheimer’s disease.*

Overall, the results support the feasibility and favorable safety profile of outpatient TPE using peripheral venous access.

“These real-world data provide insights into how the procedure performs in routine clinical practice and over an extended follow-up period. The observed cognitive and safety outcomes are encouraging and support our efforts to continue generating evidence on the potential of this approach in Alzheimer’s disease,” said Dr. Mercè Boada, founder and Senior Medical Advisor of Ace Alzheimer Center Barcelona.

“These results complement the clinical evidence generated with AMBAR and provide relevant information on the feasibility of plasma exchange with albumin replacement under routine clinical practice conditions. Our goal is to continue advancing scientific knowledge of this approach,” said Dr. Antonio Páez, VP, Neuro Innovation Hub at Grifols.

Presentation of results at CTAD and SEN

The new data are being presented today at two leading scientific meetings. At the 19th Clinical Trials on Alzheimer’s Disease Conference (CTAD) 2026, taking place in Boston from November 16 to 19, two presentations will highlight the findings: one focused on the safety and feasibility of outpatient TPE and the other on patients’ cognitive outcomes over 18 months of follow-up.

Dr. Yahveth Cantero-Fortiz, Head of the Therapeutic Apheresis Unit at Ace, will also present the results at the 78th Annual Meeting of the Spanish Society of Neurology (SEN) in Seville, during a seminar focused on advances in plasma exchange with albumin replacement in Alzheimer’s disease.

From clinical research to real-world evaluation

The new data add to the body of research generated by the program. The AMBAR clinical study showed a 61% reduction in disease progression in patients with mild to moderate Alzheimer’s disease compared with untreated patients.[1] Grifols and Ace Alzheimer Center Barcelona jointly develop the program through the AMBAR Center in Barcelona.

The new real-world data provide additional information regarding the implementation of the AMBAR procedure in a real-world healthcare setting and contribute to the ongoing evaluation of its safety, feasibility and potential clinical relevance for people with Alzheimer’s disease.


* Observed rates of cognitive decline in this study may differ from those reported in natural history studies because of differences in study design, patient populations and other factors; therefore, direct comparisons should be interpreted with caution.

[1] Boada M, López OL, Olazarán J, Núñez L, Pfeffer M, Paricio M, Lorites J, Piñol-Ripoll G, Gámez JE, Anaya F, Kiprov D, Lima J, Grifols C, Torres M, Costa M, Bozzo J, Szczepiorkowski ZM, Hendrix S, Páez A. A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study. Alzheimers Dement. 2020 Oct;16(10):1412-1425. doi: 10.1002/alz.12137.

Medienkontakte

Sie sind Journalist oder Medienprofi?

Unser Media Relations Team ist erreichbar unter:
(+34) 93 571 00 02
media@grifols.com.

Nur für Medienanfragen.

Sie sind kein Journalist? 

Für allgemeine Anfragen wenden Sie sich bitte an corporatecomms@grifols.com.